Adherence to professional society guidelines among women with stress or mixed urinary incontinence.
claims analysis
clinical guidelines
patient management
patient outcome
urinary incontinence
Journal
Neurourology and urodynamics
ISSN: 1520-6777
Titre abrégé: Neurourol Urodyn
Pays: United States
ID NLM: 8303326
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
15
03
2022
received:
23
12
2021
accepted:
19
05
2022
pubmed:
23
6
2022
medline:
28
7
2022
entrez:
22
6
2022
Statut:
ppublish
Résumé
The objective of this analysis was to describe longitudinal adherence with recommended urinary incontinence (UI) evaluation and treatment guidelines over a 2-year period in patients newly diagnosed with stress (SUI) or mixed UI (MUI), and average 2-year cost associated with initial treatment. A retrospective claims analysis using the IBM MarketScan database was conducted. Women diagnosed with SUI/MUI between July 1, 2014 and June 30, 2016 were identified using the International Classification of Diseases (ICD) 9 and 10 codes for SUI or MUI. Newly diagnosed SUI/MUI patients who did not have a UI-related diagnosis for at least 1 year before their index date were assessed. 103 813 patients with newly diagnosed SUI or MUI were identified. Of those, 96.15% (99 821/103 813) received an initial evaluation in accordance with professional guidelines (e.g., patient history, physical examination, urinalysis). Only 6.8% (5086/74 925) and 7.7% (2229/28 888) of patients with SUI and MUI, respectively, received a first-line behavioral treatment (e.g., pelvic floor muscle exercises, bladder training), according to guidelines. The 2-year average UI-related medical costs associated with guideline adherence for SUI were $5770.93 ± $9454.81 and for MUI, $4416.16 ± $7401.53. Nonadherence was observed in 59.2% (44 382/74 925) of SUI and 64.1% (18 530/28 888) of MUI patients. Two-year average UI-related medical costs for the nonadherent group were $8568.00 ± $11 275.52 for SUI and $6986.66 ± $10 765.55 for MUI, significantly more than the adherent group (p < 0.0001). The majority of SUI or MUI patients do not receive a documented behavioral intervention as their first-line treatment, which is a recommendation by professional society guidelines. This was found to affect the cost burden for payers; those that were nonadherent had significantly higher costs 2-year postindex.
Identifiants
pubmed: 35731185
doi: 10.1002/nau.24986
pmc: PMC9542296
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1489-1497Informations de copyright
© 2022 Renovia Inc. Neurourology and Urodynamics published by Wiley Periodicals LLC.
Références
Cochrane Database Syst Rev. 2011 Dec 07;(12):CD009508
pubmed: 22161451
J Urol. 2018 Oct;200(4):848-855
pubmed: 29730202
Neurourol Urodyn. 2022 Aug;41(6):1489-1497
pubmed: 35731185
J Urol. 2017 Oct;198(4):875-883
pubmed: 28625508
Ann Intern Med. 2014 Sep 16;161(6):429-40
pubmed: 25222388
Obstet Gynecol. 2014 Jan;123(1):141-148
pubmed: 24463674
Curr Urol Rep. 2011 Oct;12(5):358-62
pubmed: 21847532
Breast. 2010 Apr;19(2):120-7
pubmed: 20117932
Am Fam Physician. 2019 Sep 15;100(6):339-348
pubmed: 31524367
Neurourol Urodyn. 2002;21(5):482-5
pubmed: 12232885
BJU Int. 2020 May;125(5):638-655
pubmed: 31625673
Rev Diabet Stud. 2004 Spring;1(1):29-38
pubmed: 17491662
BMC Health Serv Res. 2015 Apr 09;15:150
pubmed: 25880898
J Gynecol Obstet Hum Reprod. 2020 Oct;49(8):101842
pubmed: 32592767
JBI Database System Rev Implement Rep. 2017 May;15(5):1350-1408
pubmed: 28498174
Neurourol Urodyn. 2010;29(1):4-20
pubmed: 19941278
Int Urogynecol J Pelvic Floor Dysfunct. 2008 Jan;19(1):5-33
pubmed: 18026681
Female Pelvic Med Reconstr Surg. 2022 Apr 1;28(4):181-187
pubmed: 35030139
Obstet Gynecol. 2001 Sep;98(3):398-406
pubmed: 11530119